Precigen, Inc. (PGEN)
7.70
-0.11
(-1.41%)
USD |
NASDAQ |
Oct 12, 13:56
Precigen Free Cash Flow (Quarterly) : -18.20M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.20M |
| March 31, 2026 | -44.08M |
| December 31, 2025 | -23.48M |
| September 30, 2025 | -29.46M |
| June 30, 2025 | -19.94M |
| March 31, 2025 | -16.95M |
| December 31, 2024 | -9.271M |
| September 30, 2024 | -23.62M |
| June 30, 2024 | -25.43M |
| March 31, 2024 | -18.44M |
| December 31, 2023 | -16.81M |
| September 30, 2023 | -17.24M |
| June 30, 2023 | -15.87M |
| March 31, 2023 | -18.54M |
| December 31, 2022 | -15.45M |
| September 30, 2022 | -25.39M |
| June 30, 2022 | -8.771M |
| March 31, 2022 | -20.36M |
| December 31, 2021 | -17.36M |
| September 30, 2021 | -19.29M |
| June 30, 2021 | -8.97M |
| March 31, 2021 | -17.40M |
| December 31, 2020 | -17.94M |
| September 30, 2020 | -20.03M |
| June 30, 2020 | -15.69M |
| Date | Value |
|---|---|
| March 31, 2020 | -30.90M |
| December 31, 2019 | -36.83M |
| September 30, 2019 | -34.92M |
| June 30, 2019 | -47.30M |
| March 31, 2019 | -54.76M |
| December 31, 2018 | -48.60M |
| September 30, 2018 | -37.58M |
| June 30, 2018 | -38.98M |
| March 31, 2018 | -40.66M |
| December 31, 2017 | -47.87M |
| September 30, 2017 | -36.42M |
| June 30, 2017 | -35.48M |
| March 31, 2017 | -31.03M |
| December 31, 2016 | -35.63M |
| September 30, 2016 | -26.15M |
| June 30, 2016 | -10.98M |
| March 31, 2016 | -15.11M |
| December 31, 2015 | 9.424M |
| September 30, 2015 | 49.79M |
| June 30, 2015 | -20.55M |
| March 31, 2015 | -15.75M |
| December 31, 2014 | -10.23M |
| September 30, 2014 | -8.076M |
| June 30, 2014 | -14.42M |
| March 31, 2014 | 6.497M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | -2.133M |
| Aldeyra Therapeutics, Inc. | -4.612M |
| Repligen Corp. | 26.70M |
| AC Immune SA | -- |
| Amgen, Inc. | 3.489B |